RxDoctor Payments DataLook up a doctor →

Liet le, MD

Procedural Dermatology · Kingwood, TXNPI 1477726214

Payments from drug & device makers

$90,061in general payments, 2019–2025

Across 1,258 payments — averaging $71.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$34K
  • Lilly USA, LLC$29K
  • Galderma Laboratories, L.p.$4K
  • Dermavant Sciences, Inc.$4K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$2K
  • Journey Medical Corporation$2K
  • plus $15K from 33 others

What the payments were for

  • Consulting fees$5,1306%
  • Speaking & faculty fees$56,17962%
  • Travel & lodging$2,2302%
  • Food & beverage$26,04529%
  • Education$4781%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,061 in reported general payments places this provider in the 90th percentile of 25 procedural dermatology providers in Texas.

See all procedural dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$539,857
Medicare patients
841
Services billed
7,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$293,088
Humira(Cf) PenAdalimumab27$255,122
Taltz AutoinjectorIxekizumab13$88,462
Enbrel SureclickEtanercept11$80,988
Tacrolimus105$22,138
JubliaEfinaconazole16$11,967
Calcipotriene36$7,193
Ketoconazole403$5,677
Triamcinolone Acetonide312$4,855
Fluocinonide140$4,639
Betamethasone Dipropionate108$4,471
Doxycycline Hyclate45$3,186
Doxycycline Monohydrate132$2,692
Tretinoin26$2,544
Finasteride163$2,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$2,043$11,96716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 25 procedural dermatology providers in Texas.

Other procedural dermatology in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →